No black box warning on record for Voydeya

As of the latest FDA labeling reviewed, Voydeya (DANICOPAN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Voydeya medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatic Enzyme Increases: Assess liver enzymes before treatment initiation and periodically during treatment. Consider treatment interruption or discontinuation if elevations are clinically significant or if the patient becomes symptomatic ( 5.3 ). Hyperlipidemia: Monitor serum lipids periodically during treatment and initiate cholesterol-lowering medication if indicated

No black box warning on record for Voydeya

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatic Enzyme Increases: Assess liver enzymes before treatment initiation and periodically during treatment. Consider treatment interruption or discontinuation if elevations are clinically significant or if the patient becomes symptomatic ( 5.3 ). Hyperlipidemia: Monitor serum lipids periodically during treatment and initiate cholesterol-lowering medication if indicated

Voydeya Black Box Warning

No black box warning on record for Voydeya

Other warnings & precautions

Voydeya Black Box Warning

No black box warning on record for Voydeya

Other warnings & precautions